ALMIRALL, S.A. «...678910...» Page 9 out of 18 18/05/2022 17:22 ALMIRALL, S.A. Liquidity and counterparty agreements Operaciones del contrato de liquidez durante el primer trimestre de 2022 Register number: 16344 09/05/2022 07:10 ALMIRALL, S.A. On business and financial situation Almirall files First Quarter results presentation for 2022 Register number: 16115 09/05/2022 07:05 ALMIRALL, S.A. On business and financial situation Almirall announces that will webcast a conference to introduce and explain the results for the first quarter of 2022 Register number: 16114 09/05/2022 06:58 ALMIRALL, S.A. Other relevant information La Sociedad comunica el calendario del dividendo flexible Register number: 16113 09/05/2022 06:55 ALMIRALL, S.A. Other relevant information La Sociedad comunica información relativa al dividendo flexible Register number: 16112 09/05/2022 06:51 ALMIRALL, S.A. On corporate governance Acuerdos adoptados por el Consejo de Administración Register number: 16111 09/05/2022 06:46 ALMIRALL, S.A. Announcement of general shareholders’ meeting Acuerdos adoptados en Junta General Ordinaria de la Sociedad Register number: 16110 11/04/2022 16:15 ALMIRALL, S.A. Other relevant information Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis Register number: 15561 30/03/2022 08:06 ALMIRALL, S.A. Other relevant information Presentation of 16 weeks data for Lebrikizumab ADvocate 1 & 2 Phase 3 studies: Webcast with analysts and institutional investors + Presentation Register number: 15269 26/03/2022 14:21 ALMIRALL, S.A. On business and financial situation 16 weeks data for Lebrikizumab ADvocate 1 & 2 Phase 3 studies has been announced today at the American Academy of Dermatology (AAD) Annual Meeting Register number: 15183 Page 9 out of 18 «...678910...»
